Prof. Dr. Gaia Novarino
Institute of Science and Technology Austria
Anniversary brochure contribution by Gaia Novarino
DOWNLOAD
File size: 837 kB
Researcher's Profile
Research interests:
- Molecular basis of human neuropsychiatric and neurodevelopmental disorders
- Transporters in brain disorders
- Human Genetics
- Stem cell models of human neurological disorders
- Mouse models of human neurological disorders
Career highlights:
- From 09/2021 - Vice President for Science and Education, IST Austria
- Since 2019 – Full Professor at IST Austria, Klosterneuburg, Austria
- 2016 – Present Vice Chair of FENS-Kavli Network of Excellence
- 2014 – 2019 Assistant Professor, IST Austria
- 2010 – 2013 Postdoc Fellow, Joseph Gleeson Lab, UCSD, California, USA
- 2006 – 2010 Postdoc Fellow, Thomas Jentsch Lab, MDC, Berlin, Germany
Selected Grants and Awards:
- 2016 Boehringer Ingelheim FENS Research Award 2016
- 2016 ERC Starting Grant
- 2016 Simons Foundation Autism Research Initiative (SFARI) Investigator Award
- 2016 appointment as FENS KAVLI Scholar
- 2015 – 2018 Partner in the SFB35 – Transmembrane Transporters in Health and Disease
- DFG Research 2 year fellowship
- CURE (Citizens United for Research in Epilepsy) young investigator travel award
Ongoing MolTag research projects as supervisor:
- Lena SCHWARZ: The role of ASD high-risk candidate genes on a cellular and molecular level
Ongoing projects as Co-Supervisor:
- Mojtaba TAVAKOLI: Expansion microscopy for molecular interrogation of neuronal specimen
Completed projects as supervisor:
- Jasmin MORANDELL: Illuminating the Role of Cul3 in Autism Spectrum Disorder Pathogenesis, finished 08/2020
- Dora TARLUNGEANU: Role of the LAT1 transporter in brain development and autism spectrum disorders, finished 02/2018
- Lisa KNAUS: The role of Slc7a5 in neurodevelopment and neuronal survival; finished 05/2023
Completed projects as co-supervisor:
- Eva GSCHAIDER-REICHHART: Red light controlled growth factor receptors in all optical drug screening, finished 11/2017
- Stephanie KAINRATH: Synthetic tools for optogenetic and chemogenetic inhibition of cellular signals, finished 12/2019